Adrenal Insufficiency and Addison's Disease

Adrenal insufficiency is a condition in which the adrenal glands fail to produce adequate levels of cortisol, aldosterone, or both — hormones essential for metabolic regulation, immune response, and blood pressure stability. Addison's disease refers specifically to primary adrenal insufficiency, where the glands themselves are damaged or destroyed. This page covers the classification, physiological mechanism, clinical presentations, and the diagnostic and treatment decision boundaries that distinguish adrenal insufficiency types.

Definition and scope

Adrenal insufficiency is classified along a primary, secondary, and tertiary axis, each reflecting a different point of failure in the hypothalamic-pituitary-adrenal (HPA) axis.

Primary adrenal insufficiency (Addison's disease): The adrenal cortex itself is damaged, producing insufficient cortisol and, in most cases, aldosterone. Autoimmune destruction accounts for approximately 80–90% of primary cases in high-income countries, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Secondary adrenal insufficiency: The pituitary gland fails to secrete adequate adrenocorticotropic hormone (ACTH), leaving the adrenal glands understimulated. Aldosterone production is typically preserved because it is regulated primarily by the renin-angiotensin system rather than ACTH.
Tertiary adrenal insufficiency: The hypothalamus fails to release corticotropin-releasing hormone (CRH). The most common cause is prolonged exogenous glucocorticoid therapy causing HPA axis suppression.

Addison's disease carries a named diagnostic history: Thomas Addison first described the clinical syndrome in 1855 in his monograph On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules. The condition affects an estimated 93–140 per million people in Western populations, as reported in literature referenced by the National Adrenal Diseases Foundation (NADF).

The full landscape of adrenal and endocrine conditions — including the regulatory environment governing their clinical management — is outlined across resources like Regulatory Context for Endocrinology, which covers the oversight frameworks relevant to endocrine practice in the United States.

How it works

The HPA axis operates as a hormonal feedback loop. The hypothalamus releases CRH, which signals the anterior pituitary to secrete ACTH. ACTH then stimulates the adrenal cortex — specifically the zona fasciculata — to synthesize and release cortisol. Cortisol feeds back to suppress both CRH and ACTH production, maintaining equilibrium.

In primary adrenal insufficiency, the adrenal cortex is structurally or functionally compromised. Because ACTH cannot trigger adequate cortisol output, negative feedback fails, and ACTH levels rise — sometimes markedly. This ACTH excess stimulates melanocortin receptors in the skin, producing the hyperpigmentation characteristic of Addison's disease. Aldosterone deficiency — which occurs in primary but not secondary or tertiary forms — leads to sodium wasting, potassium retention, and volume depletion.

In secondary and tertiary insufficiency, low ACTH means the adrenal cortex is understimulated but not intrinsically damaged. Aldosterone synthesis remains near-normal. Hyperpigmentation does not occur because ACTH levels are low, not elevated.

The adrenal crisis — a life-threatening acute decompensation — can occur when physiological stress (infection, surgery, trauma) demands a cortisol surge that insufficient adrenal tissue cannot provide. The Endocrine Society classifies adrenal crisis as a medical emergency requiring immediate parenteral hydrocortisone, typically 100 mg intravenously as an initial dose per clinical guidance protocols.

Hormone replacement therapy for adrenal and pituitary axis disorders is discussed in detail at Hormone Replacement for Adrenal and Pituitary Conditions.

Common scenarios

Adrenal insufficiency presents across a range of clinical contexts. The following structured breakdown covers the principal scenarios encountered in endocrine practice:

Autoimmune Addison's disease: The adrenal cortex is targeted by autoantibodies — most commonly 21-hydroxylase antibodies. Onset is insidious, with fatigue, weight loss, salt craving, postural hypotension, and hyperpigmentation accumulating over months to years. Approximately 50% of patients with autoimmune Addison's disease have at least one other autoimmune condition, such as autoimmune thyroid disease or type 1 diabetes (NIDDK).
Iatrogenic (glucocorticoid-induced) adrenal insufficiency: Long-term glucocorticoid therapy suppresses CRH and ACTH secretion. When the exogenous steroid is tapered too rapidly, the HPA axis — having been suppressed — cannot recover quickly enough to maintain cortisol levels. This is the most common cause of adrenal insufficiency globally.
Adrenal crisis in known Addison's patients: Intercurrent illness is the most frequent precipitant. Patients on stable replacement doses require stress dosing — typically doubling or tripling the oral hydrocortisone dose during febrile illness — to match the cortisol surge that an intact axis would produce.
Incidental discovery: Adrenal imaging for unrelated indications occasionally reveals bilateral adrenal hemorrhage, infiltrative disease (tuberculosis remains a leading infectious cause), or metastatic deposits that have compromised adrenal cortical reserve.
Pituitary pathology-driven secondary insufficiency: Pituitary adenomas, surgery, radiation, or Sheehan syndrome (postpartum pituitary infarction) can reduce ACTH output, producing secondary insufficiency without mineralocorticoid deficit.

Patients experiencing persistent unexplained fatigue, hypotension, or electrolyte abnormalities consistent with adrenal pathology are discussed under the referral threshold guidance at Adrenal and Pituitary Symptoms.

Decision boundaries

Distinguishing primary from secondary adrenal insufficiency — and confirming insufficiency versus intact reserve — requires structured biochemical testing. The Endocrine Society Clinical Practice Guideline on Adrenal Insufficiency provides the primary reference framework for this process.

Key diagnostic distinctions:

Parameter	Primary (Addison's)	Secondary/Tertiary
Cortisol	Low	Low
ACTH	High (>2× upper limit)	Low or inappropriately normal
Aldosterone	Low	Normal
Sodium	Low	Low or normal
Potassium	High	Normal
Skin pigmentation	Present	Absent

The short Synacthen (cosyntropin) stimulation test is the standard confirmatory tool: 250 mcg synthetic ACTH is administered, and serum cortisol is measured at 30 and 60 minutes. A peak cortisol below 18 mcg/dL (500 nmol/L) is generally considered an insufficient response, though laboratory-specific cutoffs vary by assay. The NIDDK describes this test as the most reliable standard measure of adrenal reserve.

Treatment decision structure:

Glucocorticoid replacement is required in all forms. Hydrocortisone (15–25 mg/day in divided doses) most closely mimics physiological cortisol rhythm. Prednisone and dexamethasone are alternatives with longer half-lives.
Mineralocorticoid replacement (fludrocortisone, typically 0.05–0.2 mg/day) is required in primary insufficiency only, to compensate for aldosterone deficiency.
Sick-day rules and emergency protocols: Patients must carry an emergency injectable hydrocortisone kit (100 mg). Medic-alert identification is recommended by the Endocrine Society for all confirmed adrenal insufficiency patients.
Monitoring targets symptom control, blood pressure, electrolytes, and avoidance of over-replacement (which accelerates osteoporosis and metabolic risk).

The broader context of endocrine diagnostic testing — including adrenal function panels — is covered at Adrenal Function Testing. For an overview of the full scope of endocrine conditions and how they are managed across the specialty, the site index provides a structured entry point to related clinical topics.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)